N/A
Manufactured by Hisamitsu Pharmaceutical Co., Inc.
1,107 FDA adverse event reports analyzed
Last updated: 2026-04-15
MENTHOL, METHYL SALICYLATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Hisamitsu Pharmaceutical Co., Inc.. The most commonly reported adverse reactions for MENTHOL, METHYL SALICYLATE include DRUG INEFFECTIVE, APPLICATION SITE PAIN, INTENTIONAL PRODUCT MISUSE, APPLICATION SITE ERYTHEMA, DYSPNOEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for MENTHOL, METHYL SALICYLATE.
Out of 535 classified reports for MENTHOL, METHYL SALICYLATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 1,107 FDA FAERS reports that mention MENTHOL, METHYL SALICYLATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, APPLICATION SITE PAIN, INTENTIONAL PRODUCT MISUSE, APPLICATION SITE ERYTHEMA, DYSPNOEA, PAIN. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Hisamitsu Pharmaceutical Co., Inc. in connection with MENTHOL, METHYL SALICYLATE. Always verify the specific product and NDC with your pharmacist.